Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis
The Competitive Intelligence report Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis describes product portfolios and R&D pipelines of granulocyte colony stimulating factor (G-CSF) and GM-CSF products and product candidates in regulated and in less regulated markets as of July 2015. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
With 2014 sales of about US$ 6 bln, first and next generation G-CSF products represent an attractive market size for biosimilar proteins in regulated markets. Biosimilar filgrastim products have already been introduced into the the European Union and now are also entering the US market. Importantly, biosimilar products from Indian companies are among the approved products indicating that Indian companies can fulfill Western standards of cGMP manufacturing and cGCP development of at least relatively simple therapeutic proteins such as filgrastim.
The report includes a compilation of currently marketed branded and non-branded G-CSF and GM-CSF products in regulated and less regulated markets for treatment of chemotherapy-induced neutropenia. The report includes the market size of branded G-CSF products in 2014. In addition, the report lists company-specific product portfolios and R&D pipelines of G-CSF/GM-CSF products and projects. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Product Category,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.